ArticleFrontiers in immunology2026
A prospective real-world study of efgartigimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the short-term clinical efficacy and safety of efgartigimod in the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in a real-world setting. Methods: This prospective real-world study enrolled 12 CIDP patients receiving efgartigimod treatment at the Department of Neurology, The First Affiliated Hospital of Chongqing Medical University. Efficacy was comprehensively assessed using the Medical Research Council (MRC) scale for muscle strength, the inflammatory Rasch-built Overall Disability Scale (I-RODS) for disability, and the Inflammatory Neuropathy Cause and Treatment (INCAT) scale. Assessments were performed before the first dose and one week after each subsequent dose. Adverse events during treatment, concomitant use of other immunosuppressants, routine laboratory tests, electrocardiograms, and immunoglobulin levels before and after treatment were recorded. Results: Among the 12 patients, 50% received subcutaneous injection and 50% received intravenous infusion of efgartigimod. During the follow-up period, significant efficacy was observed overall, MRC scores increased from 45.92 ± 15.69 to 55.00 ± 10.14, I-RODS scores increased from 49.25 ± 24.21 to 75.42 ± 28.46, and INCAT scores decreased from 4.42 ± 3.20 to 1.42 ± 2.61. By the end of the follow-up at the fifth week after the first dose, 11 patients (91.7%) achieved clinical improvement. No significant difference in efficacy was found between the subcutaneous and intravenous administration routes. Laboratory tests showed a downward trend in IgG levels after treatment, with no significant decrease in albumin. The incidence of adverse events during treatment was low, with only one patient experiencing a localized rash. Conclusion: This study demonstrates the short-term efficacy and safety of efgartigimod in treating CIDP, suggesting its potential as a safe and effective alternative therapy. Further exploration is needed to determine its suitability for long-term maintenance treatment of CIDP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.